89bio Announces Pricing of Upsized Public Offering of Common Stock
SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of an upsized underwritten public offering of 3,300,000 shares of its common stock at a public offering price of$28.00 per share.
- SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of an upsized underwritten public offering of 3,300,000 shares of its common stock at a public offering price of$28.00 per share.
- The gross proceeds of the offering to 89bio, before deducting the underwriting discount and other offering expenses payable by 89bio, are expected to be approximately$84.7 million.
- In addition,89bio has granted the underwriters a 30-day option to purchase up to an additional 495,000 shares of common stock, at the public offering price, less the underwriting discounts and commissions.
- 89bio will not receive any proceeds from the sale of shares of the companys common stock by the selling stockholder.